Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.
Status:
Unknown status
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in
the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical
efficacy has been shown in adult with head and neck cancer. The study assessed the safety and
efficacy of different dosage of Nimotuzumab in second or late- line treatment of patients
with locally advanced or metastatic esophageal squamous cell carcinomas.